Multiple cellular pathways and enzymes

The designation "Multiple cellular pathways and enzymes" does not refer to a single molecular target but is a collective term used to describe drugs with pleiotropic effects across various biological systems (StatPearls, 2023). This classification is often applied to therapeutic agents that lack a singular, well-defined mechanism of action, instead interacting with a diverse array of receptors, transporters, and catalytic proteins (Nature Reviews Drug Discovery, 2007). For example, certain metabolic regulators and multi-kinase inhibitors are categorized this way because their clinical utility arises from the simultaneous modulation of several signaling cascades, such as the MAPK/ERK or PI3K/Akt pathways (PubMed, 2015). Because it encompasses a broad range of biological activities, this "target" cannot be mapped to a specific genetic locus or protein structure in databases like UniProt (UniProt, 2024). For biotech analysts, this term signifies a complex pharmacological profile that may offer broad efficacy but also presents significant challenges in monitoring off-target toxicity and developing specific companion diagnostics (NIH, 2021). In clinical trial registries, this phrase is sometimes used as a placeholder when the exact molecular mechanism is proprietary or when the drug's effect is systemic rather than localized to a single protein (ClinicalTrials.gov, 2023). Consequently, it does not align with the conventional "one drug, one target" paradigm of modern drug discovery (Trends in Pharmacological Sciences, 2012). This lack of specificity often necessitates more rigorous safety monitoring during development to account for unpredictable interactions across different tissue types (FDA, 2022).

Other names

Multi-targetPleiotropic targetsNon-specific cellular pathways

Pleiotropic modulation of various intracellular signaling cascades and enzymatic activities (StatPearls, 2023).